<span item_type="fundamental" item_id="d3173fb9738a339073d0c284a48388bd" counter_id="ST/US/CLDX" env="prod"></span><span item_type="announcement" item_id="645943587477194881" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 15 K.</p><p>EPS: As of FY2026 Q1, the actual value is USD -1.18, missing the estimate of USD -1.163.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -90.19 M.</p><p></p><h4>Cash Position</h4><ul><li>Cash, cash equivalents, and marketable securities were $451.5 million as of March 31, 2026, compared to $518.6 million as of December 31, 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li><li>Cash used in operating activities was $65.6 million for the first quarter of 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li><li>In April 2026, Celldex Therapeutics, Inc. raised $345.0 million in gross proceeds from a follow-on public offering, resulting in approximately $323.9 million in net proceeds <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li><li>As of March 31, 2026, Celldex Therapeutics, Inc. had 66.6 million shares outstanding <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li></ul><h4>Revenues</h4><ul><li>Total revenue for the first quarter of 2026 was $0.0 million ($15 thousand), a decrease from $0.7 million ($695 thousand) for the comparable period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li><li>Product development and licensing agreements generated $0.0 million in Q1 2026, down from $50 thousand in Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li><li>Contracts and grants contributed $15 thousand in Q1 2026, compared to $645 thousand in Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li></ul><h4>Operating Expenses</h4><ul><li>Research and development (R&amp;D) expenses increased to $73.0 million in the first quarter of 2026 from $52.6 million in the comparable period of 2025, primarily due to increased barzolvolimab clinical trial and contract manufacturing expenses, and higher employee headcount <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li><li>General and administrative (G&amp;A) expenses rose to $11.4 million in Q1 2026 from $10.8 million in Q1 2025, mainly due to increased barzolvolimab commercial planning expenses <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li></ul><h4>Operating Loss</h4><ul><li>The operating loss for the first quarter of 2026 was -$84.4 million, compared to -$62.7 million for the same period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li></ul><h4>Investment and Other Income, Net</h4><ul><li>Investment and other income, net, was $5.75 million for Q1 2026, down from $8.943 million for Q1 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li></ul><h4>Net Loss</h4><ul><li>The net loss for the first quarter of 2026 was -$78.7 million, or -$1.18 per share, compared to a net loss of -$53.8 million, or -$0.81 per share, for the comparable period in 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li></ul><h4>Operational Metrics</h4><ul><li>Enrollment was completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria (CSU) studies (EMBARQ-CSU 1 and 2), with 1,939 patients enrolled across 43 countries and over 500 sites <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li><li>The Phase 3 barzolvolimab cold urticaria (ColdU) and symptomatic dermographism (SD) study (EMBARQ-ColdU and -SD) is actively enrolling patients <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li><li>Enrollment has concluded in the Phase 2 study for prurigo nodularis (PN) and the Phase 2 study for atopic dermatitis (AD) <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li><li>Enrollment is complete in the multi-part Phase 1 study for CDX-622 in healthy volunteers, and a Phase 1 proof of mechanism (POM) study for CDX-622 in asthma patients was initiated in January 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li></ul><h4>Outlook / Guidance</h4><ul><li>Celldex Therapeutics, Inc. anticipates topline data from its Phase 3 barzolvolimab CSU studies in Q4 2026, with a BLA submission planned for 2027 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>. Topline data from the Phase 2 PN study are expected in summer 2026, and from the Phase 2 AD study in late 2026 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>. The company expects its current cash, cash equivalents, and marketable securities, combined with the net proceeds from the April 2026 public offering, to fund planned operations through 2028 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/exh_991.htm"></span>.</li></ul>

Celldex Therap | 8-K: FY2026 Q1 Revenue: USD 15 K